Matt Henriksen

Yeah.

And so, I mean, we're focused on carb counting.

Is that kind of the key kind of benefit, ease of use that the patients get?

Are there other ones as well that are worthwhile to note here?

I have a question.

How do the engineers at Beta Bionics enjoy or maybe not so much enjoy the fact that you're a user as well and you can give some first person inputs on the device?

Oh, yeah.

And so then, you know, kind of leading up to the launch itself a few years ago, you know, the randomized pivotal trial data came out.

What was some of the highlights of that data that kind of pointed to these benefits that we've been discussing?

Yeah, well, it kind of sounds like, you know, those set it and forget it type of functions is that's the most beneficial for those who didn't really try to care about carb counting in the first place.

Yeah.

And, you know, moving then into the actual launch itself, you're up to nearly, if I'm correct, if I'm wrong, 30,000 islet users.

How has that launch been to get to that accelerated of a patient base?

And then, you know, the other thing too, just kind of thrown in there, and maybe I'm answering my own question here is the...

transition into using the pharmacy channel is something that you guys have highlighted a lot about.

And so maybe we can just start there.

And, you know, the different channels that these patients can get these durable insulin pumps and why switching into the pharmacy channel has been a benefit for

you know, it seems like for you, the patients and the payers.

Well, you know, it's interesting about the pay-as-you-go model, but it sounds like, you know, you're willing to... I mean, there's the opportunity cost of some of that upfront revenue for, you know, further payouts down the road.

What makes you feel comfortable about that model?